Ascelia Pharma AB ACE
OMXSTO · Sweden · Health Technology
SEK 0.7990+0.01 (+0.88%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MALMÖ, SE / ACCESS Newswire / September 24, 2026 / AB (publ) (STO:ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced the publication of a peer-reviewed article related to Orviglance® in the Journal of Magnetic Resonance Imaging (JMRI), one of the leading peer-reviewed journals in the field of magnetic resonance imaging.The article, titled "Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Ascelia-Manganese-Based MRI C
MALMÖ, SE / ACCESS Newswire / September 10, 2026 / (STO:ACE) completed the previously scheduled Type A meeting with the U. Food and Drug Administration (FDA) on September 9, 2026, regarding the Complete Response Letter (CRL) for the Orviglance® New Drug Application (NDA).
Despite a surprise complete response letter, Ascelia Pharma remains confident in Orviglans' approval path, with a pivotal FDA Type A meeting set for September 9th and partnership interest intact.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.